

4DMedical secures national contract with I-MED, Australia's largest diagnostic imaging network

28 June 2022

Highlights

- 4DMedical signs a nationwide contract with I-MED Radiology Network
- The agreement opens the way for delivery of 4DMedical's lung imaging technology at I-MED's Australia-wide network of more than 250 clinics
- 4DMedical and I-MED also agree to establish a Lung Centre of Excellence

Melbourne, Australia, 28 June 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the expansion of its relationship with I-MED Radiology Network (I-MED) with the signing of a nationwide contract.

Furthermore, 4DMedical and I-MED have agreed to establish a Lung Centre of Excellence leveraging 4DMedical's lung imaging technology. Combined with the nationwide agreement, this centre of excellence will enable world-class research and development activities to advance diagnostic imaging throughout Australia.

The national agreement follows an initial rollout to selected I-MED clinics

I-MED is Australia's largest outsourced provider of radiology, with more than 250 clinics nationwide, offering a range of diagnostic services to private and public hospitals. The contract comes on the back of the successful rollout of the Company's XV Technology™ across I-MED clinics located in Berwick, Brisbane, Wagga Wagga, Launceston, and Albury. 4DMedical has now delivered XV Lung Ventilation Analysis Software (XV LVAS™) scans to patients at each of these sites with disease indications including long COVID, asthma, COPD and silicosis.

This three-year agreement formalises the existing commercial arrangement and clears the way for delivery of 4DMedical's lung imaging technology to other selected clinics across the I-MED network, thereby allowing widespread use for Australian patients and their referring doctors. Multiple I-MED clinics in Sydney, Melbourne, Adelaide, and Perth are already prepared for a full national launch. The three-year agreement contains standard mechanisms for termination for insolvency or ongoing material failure to carry out provisions of the agreement. Management expects that revenue generated under the agreement will be material for the Company.

As well as being used to assist in diagnosis, the unique capability and low-dosage modality developed by 4DMedical is also proving particularly useful as a surveillance tool in understanding lung disease. This patient monitoring capability clearly illustrates evolving condition of patients' lungs and response to therapeutic interventions. As 4DMedical expands its offering through a rapidly developing product pipeline, the I-MED collaboration may provide streamlined adoption across the country, without the need for extensive pilot programs.



I-MED Radiology Network's Chief Executive Officer Dr Shrey Viranna said: *"Activating this arrangement augments I-MED's world-class diagnostic imaging offering through access to 4DMedical's unique functional lung imaging technology."*

4DMedical Managing Director and Chief Executive Officer Dr Andreas Fouras said: *"I am delighted to announce today's landmark agreement for 4DMedical which represents a significant milestone for the Company. Expansion of our proven capability nationwide means many more people will be able to access the latest technology in respiratory imaging. Beyond putting our innovative technology in the reach of more people, this deal represents a significant opportunity to drive revenue for the Company. Additionally, this agreement creates a framework for the rapid commercialisation of future 4DMedical products."*

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Melanie Leydin
Company Secretary
companysecretary@4DMedical.com

Media

Julia Maguire
+ 61 (02) 8999 3699
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand lung function of patients with respiratory diseases.

Through its flagship patented XV Technology™, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS™), which is the first and only modality that can dynamically quantify ventilation throughout the lungs. It additionally exposes the patient to lower levels of radiation relative to other diagnostic methods, a clear advantage when disease progression and therapeutic effectiveness need to be regularly monitored.

XV LVAS™ reports are prepared utilising 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the company's own revolutionary XV Scanner.

To learn more, please visit: www.4dmedical.com

About I-MED

I-MED Radiology Network is Australia's largest medical imaging network, with more than 250 clinics located in metropolitan, regional and rural communities throughout Australia. It employs over 300 radiologists and 4,500 healthcare professionals and support staff.

Working together with referrers, hospitals and other stakeholders, I-MED is committed to delivering high quality and expert care to its patients. Its network of clinics delivers tailored health services that meet the needs of local communities, while drawing on the strength of I-MED's broader national footprint.

To learn more please click here: <https://i-med.com.au/>